GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » Cash Ratio

Annovis Bio (Annovis Bio) Cash Ratio : 1.34 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Annovis Bio's Cash Ratio for the quarter that ended in Dec. 2023 was 1.34.

Annovis Bio has a Cash Ratio of 1.34. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Annovis Bio's Cash Ratio or its related term are showing as below:

ANVS' s Cash Ratio Range Over the Past 10 Years
Min: 0.06   Med: 2.52   Max: 30.32
Current: 1.34

During the past 7 years, Annovis Bio's highest Cash Ratio was 30.32. The lowest was 0.06. And the median was 2.52.

ANVS's Cash Ratio is ranked worse than
68.39% of 1525 companies
in the Biotechnology industry
Industry Median: 2.9 vs ANVS: 1.34

Annovis Bio Cash Ratio Historical Data

The historical data trend for Annovis Bio's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio Cash Ratio Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial - 13.97 30.32 3.69 1.34

Annovis Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.69 3.10 7.58 1.78 1.34

Competitive Comparison of Annovis Bio's Cash Ratio

For the Biotechnology subindustry, Annovis Bio's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annovis Bio's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Annovis Bio's Cash Ratio falls into.



Annovis Bio Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Annovis Bio's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.755/4.279
=1.34

Annovis Bio's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.755/4.279
=1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Annovis Bio  (NYSE:ANVS) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Annovis Bio Cash Ratio Related Terms

Thank you for viewing the detailed overview of Annovis Bio's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Annovis Bio (Annovis Bio) Business Description

Traded in Other Exchanges
Address
1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
Executives
Henry Iii Hagopian officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White director 227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini director, officer: President and CEO 1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy director 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty officer: Chief Financial Officer 360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M. director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831

Annovis Bio (Annovis Bio) Headlines